Health ❯ Healthcare ❯ Pharmacology

Drug Therapy

Combination Therapy EGFR Inhibitors JAK Inhibitors Pirtobrutinib Dual Antiplatelet Therapy Aspirin and Ticagrelor Pazopanib Monoclonal Antibodies Belantamab Mafodotin BTK Inhibitors Statins and Ezetimibe Belnacasan

Padcev–Keytruda Cuts Recurrence and Death Risk in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer

The companies plan regulatory discussions after presenting the late-stage results at ESMO.

Final FLAURA2 Data Show Osimertinib Plus Chemotherapy Extends Survival in EGFR-Mutant Lung Cancer

Phase 3 Trial Finds Tukysa Improves PFS in First-Line Maintenance for HER2-Positive Metastatic Breast Cancer

TACSI Trial Finds No Benefit of Dual Antiplatelet Therapy After CABG, Higher Bleeding Risk

ESC Trials Back Shorter Antiplatelet Therapy for Selected MI Patients

Inhibiting Pyroptosis with Belnacasan Resensitizes Bladder Tumors to Chemotherapy